Management
Alan Wahl, PhD
Chief Executive Officer
Dr. Alan Wahl has 30+ years of successful research and drug development experience in oncology and immunological disease. He has key contributions to the discovery and clinical development of FDA approved carboplatin, TAXOL®, and ADCETRIS®. Alan has held scientific and executive leadership positions at Bristol Myers Squibb, Seagen (Seattle Genetics), Trubion, Biogen Idec, AbbVie, and Ambrx. He is a retained advisor to numerous biotech, pharma and venture capital firms. He holds over 40 issued patents and 60 publications in oncology drug discovery and targeted cancer therapies. Alan received his MS and PhD in Biochemistry and Biophysics at the University of Rochester and his post-doctoral training at Stanford University.
Che-Leung Law, PhD
Chief Scientific Officer
Dr. Che-Leung Law has 25+ years of successful drug discovery, translational research, and clinical development experience in immunology and oncology. He was among the scientific leaders at Xcyte Therapies and Seagen (Seattle Genetics) and an executive leader at Harpoon Therapeutics. Che and his teams have advanced 15+ experimental drug programs that utilize different therapeutic modalities including T cells, engineered antibodies, antibody drug conjugates, and T cell engaging molecules from research to clinical development. He has 50+ peer reviewed publications and 20+ issued patents. Che received his PhD in Pathobiology at the University of Minnesota and his post-doctoral training at University of Washington.
Scientific Advisory Board
Edward A Clark, PhD
Chair
Dr. Edward A Clark has 40+ years of experience in basic, human, and translational immunology research and is Emeritus Professor of Microbiology and Immunology at the University of Washington (UW). He has coauthored over 350 papers. His work on the CD40 receptor and CD80 (B7)-CD28 interactions are recognized as ‘Pillars of Immunology’. He is a co-inventor of the CD180 platform technology and has 10 issued patents. Ed was a co-founder of the publicly traded biotech companies Genetic Systems and Trubion Pharmaceuticals. He has served on SABs or as an advisor for many biotech and biopharmaceutical companies and as a Chair for international immunology meetings and scientific review panels. His honors include a MERIT Award from the National Institutes of Health and a Presidential Innovation Fellowship from the UW.